Jianmin Pharmaceutical Group Co Ltd (600976) — Strategic Asset Allocation Index
Jianmin Pharmaceutical Group Co Ltd (600976) has a Strategic Asset Allocation Index of 21.8% as of June 2023. Strategic assets (PP&E of CN¥430.27 Million plus long-term investments of CN¥-) total CN¥430.27 Million, measured against net assets of CN¥1.98 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 600976 equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Jianmin Pharmaceutical Group Co Ltd Strategic Asset Allocation Index (2001–2022)
This chart shows how Jianmin Pharmaceutical Group Co Ltd's Strategic Asset Allocation Index has evolved across 22 annual periods from 2001 to 2022. As of June 2023, the index stands at 21.8%, representing strategic assets of CN¥430.27 Million against net assets of CN¥1.98 Billion CNY. For live market cap and overall valuation, see Jianmin Pharmaceutical Group Co Ltd market capitalisation.
Annual Strategic Asset Allocation Index for Jianmin Pharmaceutical Group Co Ltd (2001–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Jianmin Pharmaceutical Group Co Ltd from 2001 to 2022, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 600976 net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 22.4% | CN¥417.65 Million | CN¥417.65 Million | CN¥- | CN¥1.87 Billion | ▼ -2.9 pp |
| 2021 | 25.3% | CN¥396.65 Million | CN¥396.65 Million | CN¥- | CN¥1.57 Billion | ▼ -2.8 pp |
| 2020 | 28.1% | CN¥371.76 Million | CN¥371.76 Million | CN¥- | CN¥1.32 Billion | ▲ +0.5 pp |
| 2019 | 27.5% | CN¥332.75 Million | CN¥332.75 Million | CN¥- | CN¥1.21 Billion | ▼ -16.4 pp |
| 2018 | 44.0% | CN¥503.49 Million | CN¥273.29 Million | CN¥230.21 Million | CN¥1.15 Billion | ▲ +4.1 pp |
| 2017 | 39.9% | CN¥441.74 Million | CN¥245.55 Million | CN¥196.20 Million | CN¥1.11 Billion | ▲ +2.6 pp |
| 2016 | 37.3% | CN¥385.06 Million | CN¥239.69 Million | CN¥145.37 Million | CN¥1.03 Billion | ▲ +5.5 pp |
| 2015 | 31.9% | CN¥317.77 Million | CN¥231.26 Million | CN¥86.52 Million | CN¥997.36 Million | ▲ +9.2 pp |
| 2014 | 22.7% | CN¥227.30 Million | CN¥227.30 Million | CN¥- | CN¥1.00 Billion | ▼ -3.5 pp |
| 2013 | 26.2% | CN¥246.28 Million | CN¥246.28 Million | CN¥- | CN¥940.46 Million | ▼ -0.8 pp |
| 2012 | 27.0% | CN¥243.63 Million | CN¥243.63 Million | CN¥- | CN¥903.10 Million | ▼ -1.3 pp |
| 2011 | 28.3% | CN¥248.16 Million | CN¥248.16 Million | CN¥- | CN¥876.97 Million | ▼ -2.1 pp |
| 2010 | 30.4% | CN¥257.62 Million | CN¥257.62 Million | CN¥- | CN¥848.81 Million | ▼ -6.1 pp |
| 2009 | 36.5% | CN¥299.31 Million | CN¥299.31 Million | CN¥- | CN¥820.32 Million | ▲ +1.1 pp |
| 2008 | 35.4% | CN¥269.71 Million | CN¥269.71 Million | CN¥- | CN¥761.24 Million | ▲ +0.9 pp |
| 2007 | 34.5% | CN¥256.19 Million | CN¥256.19 Million | CN¥- | CN¥742.63 Million | ▼ -6.0 pp |
| 2006 | 40.5% | CN¥310.60 Million | CN¥310.60 Million | CN¥- | CN¥766.61 Million | ▼ -2.6 pp |
| 2005 | 43.2% | CN¥327.88 Million | CN¥327.88 Million | CN¥- | CN¥759.65 Million | ▲ +1.0 pp |
| 2004 | 42.2% | CN¥297.60 Million | CN¥297.60 Million | CN¥- | CN¥705.12 Million | ▼ -38.9 pp |
| 2003 | 81.1% | CN¥235.38 Million | CN¥235.38 Million | CN¥- | CN¥290.32 Million | ▲ +21.4 pp |
| 2002 | 59.6% | CN¥155.38 Million | CN¥155.38 Million | CN¥- | CN¥260.54 Million | ▲ +8.6 pp |
| 2001 | 51.0% | CN¥119.21 Million | CN¥119.21 Million | CN¥- | CN¥233.57 Million | — |